Literature DB >> 15759156

IgG isotype to C-terminal 19 kDa of Plasmodium vivax merozoite surface protein 1 among subjects with different levels of exposure to malaria in Brazil.

Cristiane G Morais1, Irene S Soares, Luzia H Carvalho, Cor Jesus F Fontes, Antoniana U Krettli, Erika Martins Braga.   

Abstract

Subclasses of antibodies to the C-terminal 19 kDa fragment of the Plasmodium vivax merozoite surface protein 1 (PvMSP-1(19)) were assessed among subjects with distinct degrees of malaria exposure in the Brazilian endemic area. The PvMSP-1(19) specific IgG1and IgG3 levels were low among subjects with long-term exposure (approximately 19 years) when compared to subjects less and sporadically exposed (<1 year). No statistically difference was observed in IgG subclass distribution of antibodies from symptomatic Plasmodium-infected patients, asymptomatic parasite carriers and non-infected subjects living in a same mesoendemic area. Subjects briefly exposed to a P. vivax outbreak living in a rural community outside the endemic area were also evaluated to measure the persistence of specific antibodies. IgG anti-PvMSP-1(19) antibodies persisted in 40% of the subjects who had had malarial symptoms 8 months before and decreased after 7 years (28%). Specific IgG1 were the predominant isotype. Our study emphasizes the highly immunogenicity of the PvMSP-1(19) and points toward its possible use as a potential malaria vaccine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15759156     DOI: 10.1007/s00436-005-1314-x

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  29 in total

1.  Association of the IgG response to Plasmodium falciparum merozoite protein (C-terminal 19 kD) with clinical immunity to malaria in the Brazilian Amazon region.

Authors:  Erika Martins Braga; Rosa Maria Barros; Tânia Afonso Reis; Cor Jesus F Fontes; Cristiane Guimarães Morais; Maria Sĵnia Martins; Antoniana Ursine Krettli
Journal:  Am J Trop Med Hyg       Date:  2002-05       Impact factor: 2.345

2.  Epidermal growth factor-like motifs 1 and 2 of Plasmodium vivax merozoite surface protein 1 are critical domains in erythrocyte invasion.

Authors:  Hye-Jin Han; Sae-Gwang Park; So-Hee Kim; Seung-Young Hwang; Jin Han; June Traicoff; Weon-Gyu Kho; Joon-Yong Chung
Journal:  Biochem Biophys Res Commun       Date:  2004-07-23       Impact factor: 3.575

3.  Human migration and the spread of malaria in Brazil.

Authors:  A Cruz Marques
Journal:  Parasitol Today       Date:  1987-06

4.  Anti-merozoite surface protein-1 19-kDa IgG in mother-infant pairs naturally exposed to Plasmodium falciparum: subclass analysis with age, exposure to asexual parasitemia, and protection against malaria. V. The Asembo Bay Cohort Project.

Authors:  O H Branch; A J Oloo; B L Nahlen; D Kaslow; A A Lal
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

5.  Lack of association between maternal antibody and protection of African infants from malaria infection.

Authors:  E M Riley; G E Wagner; M F Ofori; J G Wheeler; B D Akanmori; K Tetteh; D McGuinness; S Bennett; F K Nkrumah; R F Anders; K A Koram
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

6.  A Plasmodium vivax vaccine candidate displays limited allele polymorphism, which does not restrict recognition by antibodies.

Authors:  I S Soares; J W Barnwell; M U Ferreira; M Gomes Da Cunha; J P Laurino; B A Castilho; M M Rodrigues
Journal:  Mol Med       Date:  1999-07       Impact factor: 6.354

7.  Naturally acquired antibody responses to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in Korea.

Authors:  J W Park; S H Moon; J S Yeom; K J Lim; M J Sohn; W C Jung; Y J Cho; K W Jeon; W Ju; C S Ki; M D Oh; K Choe
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

8.  Inhibitory and neutral antibodies to Plasmodium falciparum MSP119 form ring structures with their antigen.

Authors:  Carien Dekker; Chairat Uthaipibull; Lesley J Calder; Matthew Lock; Munira Grainger; William D Morgan; Guy G Dodson; Anthony A Holder
Journal:  Mol Biochem Parasitol       Date:  2004-09       Impact factor: 1.759

Review 9.  Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria.

Authors:  A A Holder; J A Guevara Patiño; C Uthaipibull; S E Syed; I T Ling; T Scott-Finnigan; M J Blackman
Journal:  Parassitologia       Date:  1999-09

10.  Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains.

Authors:  M J Blackman; I T Ling; S C Nicholls; A A Holder
Journal:  Mol Biochem Parasitol       Date:  1991-11       Impact factor: 1.759

View more
  24 in total

1.  A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1.

Authors:  Paulo Afonso Nogueira; Fabiana Piovesan Alves; Carmen Fernandez-Becerra; Oliver Pein; Neida Rodrigues Santos; Luiz Hildebrando Pereira da Silva; Erney Plessman Camargo; Hernando A del Portillo
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Malaria in Brazil: an overview.

Authors:  Joseli Oliveira-Ferreira; Marcus V G Lacerda; Patrícia Brasil; José L B Ladislau; Pedro L Tauil; Cláudio Tadeu Daniel-Ribeiro
Journal:  Malar J       Date:  2010-04-30       Impact factor: 2.979

3.  Detection of Plasmodium falciparum, P. vivax, P. ovale, and P. malariae merozoite surface protein 1-p19 antibodies in human malaria patients and experimentally infected nonhuman primates.

Authors:  A Scott Muerhoff; Larry G Birkenmeyer; Ruthie Coffey; Bruce J Dille; John W Barnwell; William E Collins; Joann S Sullivan; George J Dawson; Suresh M Desai
Journal:  Clin Vaccine Immunol       Date:  2010-08-11

4.  Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection.

Authors:  I P Ceravolo; B A M Sanchez; T N Sousa; B M Guerra; I S Soares; E M Braga; A M McHenry; J H Adams; C F A Brito; L H Carvalho
Journal:  Clin Exp Immunol       Date:  2009-06       Impact factor: 4.330

5.  Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals.

Authors:  J C Lima-Junior; T M Tran; E V S Meyer; B Singh; S G De-Simone; F Santos; C T Daniel-Ribeiro; A Moreno; J W Barnwell; M R Galinski; J Oliveira-Ferreira
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

6.  Naturally-acquired humoral immune responses against the N- and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assay.

Authors:  Carmen Fernandez-Becerra; Sergi Sanz; Marina Brucet; Danielle I Stanisic; Fabiana P Alves; Erney P Camargo; Pedro L Alonso; Ivo Mueller; Hernando A del Portillo
Journal:  Malar J       Date:  2010-01-21       Impact factor: 2.979

7.  Production and characterization of mouse monoclonal antibodies recognizing multiple subclasses of human IgG.

Authors:  Fatemeh Hajighasemi; Fazel Shokri
Journal:  Avicenna J Med Biotechnol       Date:  2010-01

8.  Production and Characterization of Mouse Monoclonal Antibodies Recognizing Human Pan-IgG Specific Conformational or Linear Epitopes.

Authors:  Fatemeh Hajighasemi; Jalal Khoshnoodi; Fazel Shokri
Journal:  Avicenna J Med Biotechnol       Date:  2012-10

9.  Generation and Characterization of Mouse Hybridomas Secreting Monoclonal Antibodies Specific for Human IgG3.

Authors:  Fatemeh Hajighasemi; Fazel Shokri
Journal:  Avicenna J Med Biotechnol       Date:  2009-04

10.  Antigenicity and immunogenicity of Plasmodium vivax merozoite surface protein-3.

Authors:  Amanda R Bitencourt; Elaine C Vicentin; Maria C Jimenez; Ricardo Ricci; Juliana A Leite; Fabio T Costa; Luis C Ferreira; Bruce Russell; François Nosten; Laurent Rénia; Mary R Galinski; John W Barnwell; Mauricio M Rodrigues; Irene S Soares
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.